PL176727B1 - Sposób oznaczania stężenia farmaceutyków wiążących immunofiliny we krwi i zestaw do oznaczania stężenia farmaceutyków wiążących immunofiliny we krwi - Google Patents
Sposób oznaczania stężenia farmaceutyków wiążących immunofiliny we krwi i zestaw do oznaczania stężenia farmaceutyków wiążących immunofiliny we krwiInfo
- Publication number
- PL176727B1 PL176727B1 PL94313392A PL31339294A PL176727B1 PL 176727 B1 PL176727 B1 PL 176727B1 PL 94313392 A PL94313392 A PL 94313392A PL 31339294 A PL31339294 A PL 31339294A PL 176727 B1 PL176727 B1 PL 176727B1
- Authority
- PL
- Poland
- Prior art keywords
- binding
- rapamycin
- pharmaceutical
- competitor
- cyclosporin
- Prior art date
Links
- 230000027455 binding Effects 0.000 claims abstract description 83
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract description 74
- 229960002930 sirolimus Drugs 0.000 claims abstract description 74
- 229960001265 ciclosporin Drugs 0.000 claims abstract description 70
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract description 64
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 55
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims abstract description 55
- 108010036949 Cyclosporine Proteins 0.000 claims abstract description 54
- 229930105110 Cyclosporin A Natural products 0.000 claims abstract description 46
- 239000008280 blood Substances 0.000 claims abstract description 44
- 210000004369 blood Anatomy 0.000 claims abstract description 44
- 229930182912 cyclosporin Natural products 0.000 claims abstract description 44
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- 102000005962 receptors Human genes 0.000 claims abstract description 31
- 108020003175 receptors Proteins 0.000 claims abstract description 31
- 108010016648 Immunophilins Proteins 0.000 claims abstract description 25
- 102000000521 Immunophilins Human genes 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 11
- -1 FK506 compound Chemical class 0.000 claims abstract description 8
- 102100038796 E3 ubiquitin-protein ligase TRIM13 Human genes 0.000 claims abstract description 7
- 101000664589 Homo sapiens E3 ubiquitin-protein ligase TRIM13 Proteins 0.000 claims abstract description 7
- NGEWQZIDQIYUNV-UHFFFAOYSA-N L-valinic acid Natural products CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 claims description 11
- 230000009260 cross reactivity Effects 0.000 claims description 8
- 230000001506 immunosuppresive effect Effects 0.000 claims description 4
- 238000003556 assay Methods 0.000 description 39
- 239000000243 solution Substances 0.000 description 21
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 15
- 229920001213 Polysorbate 20 Polymers 0.000 description 14
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 14
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 14
- 108010036941 Cyclosporins Proteins 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000036765 blood level Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 229910052722 tritium Inorganic materials 0.000 description 4
- 108010068682 Cyclophilins Proteins 0.000 description 3
- 102000001493 Cyclophilins Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102000023732 binding proteins Human genes 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000037029 cross reaction Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010072220 Cyclophilin A Proteins 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 108010019249 cyclosporin G Proteins 0.000 description 2
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- TYFOVYYNQGNDKH-HHPJSCBPSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(1r,2r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23, Chemical compound CCCC[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC1=O TYFOVYYNQGNDKH-HHPJSCBPSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 241001647839 Streptomyces tsukubensis Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 108010040764 dihydrocyclosporin A Proteins 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9493—Immunosupressants
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Sampling And Sample Adjustment (AREA)
- Fishing Rods (AREA)
- Input Circuits Of Receivers And Coupling Of Receivers And Audio Equipment (AREA)
- Saccharide Compounds (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
- Sanitary Device For Flush Toilet (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939318612A GB9318612D0 (en) | 1993-09-08 | 1993-09-08 | An assay |
| PCT/EP1994/002986 WO1995007468A1 (en) | 1993-09-08 | 1994-09-07 | Assay kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL313392A1 PL313392A1 (en) | 1996-06-24 |
| PL176727B1 true PL176727B1 (pl) | 1999-07-30 |
Family
ID=10741695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL94313392A PL176727B1 (pl) | 1993-09-08 | 1994-09-07 | Sposób oznaczania stężenia farmaceutyków wiążących immunofiliny we krwi i zestaw do oznaczania stężenia farmaceutyków wiążących immunofiliny we krwi |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0717850B1 (de) |
| JP (1) | JP2892503B2 (de) |
| KR (1) | KR100313841B1 (de) |
| CN (1) | CN1088196C (de) |
| AT (1) | ATE153769T1 (de) |
| AU (1) | AU680946B2 (de) |
| BR (1) | BR9407422A (de) |
| CA (1) | CA2169162C (de) |
| CZ (1) | CZ289434B6 (de) |
| DE (1) | DE69403484T2 (de) |
| DK (1) | DK0717850T3 (de) |
| ES (1) | ES2103136T3 (de) |
| FI (1) | FI111035B (de) |
| GB (1) | GB9318612D0 (de) |
| GR (1) | GR3023578T3 (de) |
| HU (1) | HU218743B (de) |
| NO (1) | NO960924D0 (de) |
| NZ (1) | NZ273595A (de) |
| PL (1) | PL176727B1 (de) |
| RU (1) | RU2138052C1 (de) |
| SK (1) | SK281369B6 (de) |
| WO (1) | WO1995007468A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| US5650288A (en) * | 1995-07-14 | 1997-07-22 | Macfarlane; Gordon D. | Immunophilin-bound immunosuppressant assay |
| WO1997033604A1 (en) * | 1996-03-12 | 1997-09-18 | Picower Institute For Medical Research | Treatment of hiv-infection by interfering with host cell cyclophilin receptor activity |
| US6106779A (en) * | 1997-10-02 | 2000-08-22 | Biosite Diagnostics, Inc. | Lysis chamber for use in an assay device |
| ATE264863T1 (de) | 1999-08-24 | 2004-05-15 | Ariad Gene Therapeutics Inc | 28-epirapaloge |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| US7186518B2 (en) | 2003-11-21 | 2007-03-06 | Dade Behring Inc. | Method and composition useful for determining FK 506 |
| WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
| AU2006259348B2 (en) | 2005-06-17 | 2010-07-22 | Novartis Ag | Use of sanglifehrin in HCV |
| CN100434901C (zh) * | 2006-01-12 | 2008-11-19 | 上海交通大学 | 血红蛋白凝胶层析的教学试剂盒 |
| US7914999B2 (en) * | 2006-12-29 | 2011-03-29 | Abbott Laboratories | Non-denaturing lysis reagent |
| US7790401B2 (en) * | 2007-08-06 | 2010-09-07 | Siemens Healthcare Diagnostics | Methods for detection of immunosuppressant drugs |
| US8921642B2 (en) | 2008-01-11 | 2014-12-30 | Massachusetts Eye And Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
| US9658218B2 (en) | 2012-05-07 | 2017-05-23 | Siemens Healthcare Diagnostics Inc. | Determination of total analyte concentration |
| US9121859B2 (en) * | 2012-12-04 | 2015-09-01 | Siemens Healthcare Diagnostics Inc. | Compounds and methods for determination of FKBP-binding immunosuppressant drugs |
| EP3008192B1 (de) | 2013-06-11 | 2019-07-17 | Takara Bio USA, Inc. | Proteinangereicherte mikrovesikel und verfahren zur herstellung und verwendung davon |
| KR101760707B1 (ko) | 2015-01-05 | 2017-07-24 | 한림대학교 산학협력단 | 이종 알부민을 이용한 장기 이식 거부반응 검사용 키트 |
| CN104749009B (zh) * | 2015-03-30 | 2018-05-04 | 上海云泽生物科技有限公司 | 用于免疫分析的免疫抑制剂药物提取试剂 |
| CN104764883A (zh) * | 2015-03-31 | 2015-07-08 | 上海云泽生物科技有限公司 | 一种检测环孢霉素a浓度的免疫分析方法和试剂盒 |
| ES2992864T3 (en) * | 2018-11-02 | 2024-12-18 | Siemens Healthcare Diagnostics Inc | Binding competitors for use in macrophilin-binding pharmaceutical assays and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1490650A1 (ru) * | 1987-04-06 | 1989-06-30 | Институт биологической физики АН СССР | Способ количественного определени стероидных гормонов |
| DE3886265T2 (de) * | 1987-06-05 | 1994-04-28 | Fujisawa Pharmaceutical Co | Anti-FR-900506-Stoffe-Antikörper und höchstempfindliches Enzym-Immunoassay-Verfahren. |
| DE3884470T2 (de) * | 1987-06-17 | 1994-03-10 | Sandoz Ag | Cyclosporine und deren Benutzung als Arzneimittel. |
| US5322772A (en) * | 1991-04-09 | 1994-06-21 | Children's Research Institute | Rapamycin assay |
| WO1993025533A1 (en) * | 1992-06-05 | 1993-12-23 | Abbott Laboratories | Methods and reagents for the determination of immunosuppressive agents |
| GB9307491D0 (en) * | 1993-04-08 | 1993-06-02 | Sandoz Ltd | Organic compounds |
-
1993
- 1993-09-08 GB GB939318612A patent/GB9318612D0/en active Pending
-
1994
- 1994-09-07 DK DK94927577.0T patent/DK0717850T3/da active
- 1994-09-07 HU HU9600564A patent/HU218743B/hu not_active IP Right Cessation
- 1994-09-07 WO PCT/EP1994/002986 patent/WO1995007468A1/en not_active Ceased
- 1994-09-07 CZ CZ1996662A patent/CZ289434B6/cs not_active IP Right Cessation
- 1994-09-07 EP EP94927577A patent/EP0717850B1/de not_active Expired - Lifetime
- 1994-09-07 RU RU96107464A patent/RU2138052C1/ru not_active IP Right Cessation
- 1994-09-07 SK SK310-96A patent/SK281369B6/sk unknown
- 1994-09-07 PL PL94313392A patent/PL176727B1/pl unknown
- 1994-09-07 BR BR9407422A patent/BR9407422A/pt not_active Application Discontinuation
- 1994-09-07 CA CA002169162A patent/CA2169162C/en not_active Expired - Lifetime
- 1994-09-07 DE DE69403484T patent/DE69403484T2/de not_active Expired - Lifetime
- 1994-09-07 ES ES94927577T patent/ES2103136T3/es not_active Expired - Lifetime
- 1994-09-07 CN CN94193303A patent/CN1088196C/zh not_active Expired - Fee Related
- 1994-09-07 NZ NZ273595A patent/NZ273595A/en unknown
- 1994-09-07 KR KR1019960701107A patent/KR100313841B1/ko not_active Expired - Fee Related
- 1994-09-07 JP JP7508458A patent/JP2892503B2/ja not_active Expired - Lifetime
- 1994-09-07 AU AU76948/94A patent/AU680946B2/en not_active Ceased
- 1994-09-07 AT AT94927577T patent/ATE153769T1/de active
-
1996
- 1996-03-04 FI FI961004A patent/FI111035B/fi not_active IP Right Cessation
- 1996-03-07 NO NO960924A patent/NO960924D0/no unknown
-
1997
- 1997-05-29 GR GR970401194T patent/GR3023578T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6187547B1 (en) | Assay kit | |
| PL176727B1 (pl) | Sposób oznaczania stężenia farmaceutyków wiążących immunofiliny we krwi i zestaw do oznaczania stężenia farmaceutyków wiążących immunofiliny we krwi | |
| US7186518B2 (en) | Method and composition useful for determining FK 506 | |
| US7883855B2 (en) | Immunosuppressant drug extraction reagent for immunoassays | |
| US8153594B2 (en) | Tacrolimus standard and methods of using same | |
| BRPI0722361A2 (pt) | Reagente de extração de fármaco imunossupressor para imunoensaios | |
| EP1875250B1 (de) | Verfahren zur messung immunsuppressiver tacrolimus-, sirolimus- und cyclosporin-a-komplexe in einer blutprobe | |
| US7223553B2 (en) | Immunoassays for everolimus | |
| Wallemacq et al. | Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours | |
| HK1005754B (en) | Assay kit | |
| CA2004387C (en) | Cyclosporine binding protein and use in an assay for biologically-active cyclosporine | |
| Zhang et al. | Production of a sensitive antibody against sirolimus for chemiluminescence immunoassay potential in its therapeutic drug monitoring |